Researchers from the University of Bergen and the Norwegian Research Center (NORCE) have achieved a significant milestone in the decades-long effort to develop a vaccine against enterotoxigenic Escherichia coli (ETEC). This bacterium is a leading cause of severe diarrheal illness globally, disproportionately affecting children in low- and middle-income countries. The new technology specifically targets a toxin produced by ETEC, which has historically hindered vaccine development. This breakthrough technology has been licensed to the French manufacturer Valneva for further advancement. While Dr. James Fleckenstein of Washington University School of Medicine notes that the proteins elicit strong antibody responses, the technology requires extensive laboratory studies, clinical trials, and regulatory reviews before public availability. Until a vaccine is realized, experts recommend travelers practice hand hygiene and consume bottled water to mitigate the risk of infection.